Chris Lucas

Chris joined Tessera in 2022 as Senior Vice President of Financial Planning and Operational Excellence. Having over 16 years of experience across multiple industries, Mr. Lucas brings a strong background in financial management, leading and developing finance teams, operational excellence, strategic insights/planning, capital raising, and manufacturing strategy. As a member of the Tessera leadership team, he is responsible for Financial Planning & Analysis (FP&A), Procurement & Sourcing, and Manufacturing Strategy/Planning.

Before joining Tessera, Chris was the Head of Strategy and Business Operations at 2seventy bio (post bluebird bio spin-out) and previously Interim CFO of bluebird bio pre-spin remain-co. Most recently, he oversaw operating governance, clinical manufacturing construction, spin-off readiness, strategic planning & insights, FP&A, and procurement/sourcing. He originally joined bluebird bio as VP, Finance (FP&A + Global Procurement & Sourcing). Before bluebird, Chris was the Executive Director, Global FP&A at Amicus Therapeutics where he grew and developed a Global FP&A team to support the global commercial launch of Galafold, development of biologics, and multiple acquisitions to build a Gene Therapy Portfolio/Pipeline. Prior experience includes business formation consulting, hedge fund (deal origination), investment banking and equity research.

Chris has a B.B.A in Finance and Accounting and an M.B.A., both from St. Bonaventure University.